Overview Dividends

(CPRX) Catalyst Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US14888U1016

Firdapse, Fycompa, Ruzurgi, Agamree

Biotechnology
Market Cap in USD: 2,861m
IPO / Inception: 2006-11-08
Return 12m vs S&P 500: -6.72%

EPS (Earnings per Share)

EPS (Earnings per Share) of CPRX over the last years for every Quarter: "2020-09": 0.11, "2020-12": 0.11, "2021-03": 0.07, "2021-06": 0.11, "2021-09": 0.1, "2021-12": 0.09, "2022-03": 0.12, "2022-06": 0.2, "2022-09": 0.2, "2022-12": 0.22, "2023-03": 0.26, "2023-06": 0.53, "2023-09": -0.29, "2023-12": 0.31, "2024-03": 0.19, "2024-06": 0.33, "2024-09": 0.35, "2024-12": 0.7, "2025-03": 0.68, "2025-06": 0.41, "2025-09": 0.68,
EPS CAGR: 71.48%
EPS Trend: 62.8%
Last SUE: 2.76
Qual. Beats: 1

Revenue

Revenue of CPRX over the last years for every Quarter: 2020-09: 29.317, 2020-12: 31.014909, 2021-03: 30.205, 2021-06: 36.365, 2021-09: 35.954, 2021-12: 38.309, 2022-03: 43.089, 2022-06: 53.113, 2022-09: 57.244, 2022-12: 60.757, 2023-03: 85.366, 2023-06: 99.582, 2023-09: 102.688, 2023-12: 110.568, 2024-03: 98.509, 2024-06: 122.71, 2024-09: 128.695, 2024-12: 141.82, 2025-03: 141.421, 2025-06: 146.563, 2025-09: 148.392,
Rev. CAGR: 43.49%
Rev. Trend: 95.7%
Last SUE: 2.93
Qual. Beats: 5

Dividends

Currently no dividends paid
Risk via 10d forecast
Volatility 39.7%
Value at Risk 5%th 59.3%
Relative Tail Risk -9.22%
Reward TTM
Sharpe Ratio 0.34
Alpha -4.55
CAGR/Max DD 0.27
Character TTM
Hurst Exponent 0.322
Beta 0.833
Beta Downside 0.797
Drawdowns 3y
Max DD 45.37%
Mean DD 20.61%
Median DD 21.47%

Description: CPRX Catalyst Pharmaceuticals November 10, 2025

Catalyst Pharmaceuticals (NASDAQ: CPRX) is a commercial-stage biopharma that targets rare diseases in the U.S., leveraging a small-capsized portfolio to generate high-margin specialty revenues.

The company’s marketed products include Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), Fycompa (an AMPA-receptor antagonist for focal-onset and tonic-clonic seizures), Ruzurgi (a pediatric LEMS indication, launched in 2023), and AGAMREE (a corticosteroid under investigation for Duchenne muscular dystrophy.

As of the latest Q2 2024 filing, CPRX reported net product revenue of $210 million, a cash balance of $340 million, and a runway extending roughly 18 months absent additional financing, reflecting the cash-intensive nature of rare-disease commercialization.

Key sector drivers that shape CPRX’s outlook include the U.S. orphan-drug premium pricing framework (average 5-year price increase of ~12 % in the rare-disease segment), ongoing FDA incentives for accelerated approvals, and a competitive landscape where generic entry risk is mitigated by strong patent protection on its flagship assets.

For a deeper quantitative dive into CPRX’s valuation metrics, the ValueRay platform offers a concise, data-rich overview.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (217.6m TTM) > 0 and > 6% of Revenue (6% = 34.7m TTM)
FCFTA 0.22 (>2.0%) and ΔFCFTA -6.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 125.2% (prev 94.16%; Δ 31.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.22 (>3.0%) and CFO 234.7m > Net Income 217.6m (YES >=105%, WARN >=100%)
Net Debt (-687.0m) to EBITDA (304.3m) ratio: -2.26 <= 3.0 (WARN <= 3.5)
Current Ratio 6.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (127.1m) change vs 12m ago 1.34% (target <= -2.0% for YES)
Gross Margin 83.60% (prev 86.32%; Δ -2.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 63.41% (prev 59.65%; Δ 3.77pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -13.84 (EBITDA TTM 304.3m / Interest Expense TTM -19.3m) >= 6 (WARN >= 3)

Altman Z'' 11.44

(A) 0.69 = (Total Current Assets 852.5m - Total Current Liabilities 128.7m) / Total Assets 1.05b
(B) 0.42 = Retained Earnings (Balance) 446.8m / Total Assets 1.05b
(C) 0.29 = EBIT TTM 266.5m / Avg Total Assets 911.8m
(D) 3.40 = Book Value of Equity 446.9m / Total Liabilities 131.4m
Total Rating: 11.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 91.52

1. Piotroski 4.0pt
2. FCF Yield 10.79%
3. FCF Margin 40.56%
4. Debt/Equity 0.00
5. Debt/Ebitda -2.26
6. ROIC - WACC (= 14.95)%
7. RoE 26.39%
8. Rev. Trend 95.71%
9. EPS Trend 62.80%

What is the price of CPRX shares?

As of November 27, 2025, the stock is trading at USD 23.43 with a total of 1,478,115 shares traded.
Over the past week, the price has changed by +4.09%, over one month by +9.54%, over three months by +17.50% and over the past year by +6.84%.

Is CPRX a buy, sell or hold?

Catalyst Pharmaceuticals has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy CPRX.
  • Strong Buy: 6
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CPRX price?

Issuer Target Up/Down from current
Wallstreet Target Price 34.9 48.8%
Analysts Target Price 34.9 48.8%
ValueRay Target Price 25.4 8.5%

CPRX Fundamental Data Overview November 25, 2025

Market Cap USD = 2.86b (2.86b USD * 1.0 USD.USD)
P/E Trailing = 13.614
P/E Forward = 10.4822
P/S = 4.9488
P/B = 3.1087
Beta = 0.688
Revenue TTM = 578.2m USD
EBIT TTM = 266.5m USD
EBITDA TTM = 304.3m USD
Long Term Debt = 2.89m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 428.0k USD (from shortTermDebt, last quarter)
Debt = 2.89m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -687.0m USD (from netDebt column, last quarter)
Enterprise Value = 2.17b USD (2.86b + Debt 2.89m - CCE 689.9m)
Interest Coverage Ratio = -13.84 (Ebit TTM 266.5m / Interest Expense TTM -19.3m)
FCF Yield = 10.79% (FCF TTM 234.5m / Enterprise Value 2.17b)
FCF Margin = 40.56% (FCF TTM 234.5m / Revenue TTM 578.2m)
Net Margin = 37.63% (Net Income TTM 217.6m / Revenue TTM 578.2m)
Gross Margin = 83.60% ((Revenue TTM 578.2m - Cost of Revenue TTM 94.8m) / Revenue TTM)
Gross Margin QoQ = 82.94% (prev 79.56%)
Tobins Q-Ratio = 2.07 (Enterprise Value 2.17b / Total Assets 1.05b)
Interest Expense / Debt = 58.98% (Interest Expense 1.70m / Debt 2.89m)
Taxrate = 25.69% (18.3m / 71.0m)
NOPAT = 198.1m (EBIT 266.5m * (1 - 25.69%))
Current Ratio = 6.62 (Total Current Assets 852.5m / Total Current Liabilities 128.7m)
Debt / Equity = 0.00 (Debt 2.89m / totalStockholderEquity, last quarter 920.2m)
Debt / EBITDA = -2.26 (Net Debt -687.0m / EBITDA 304.3m)
Debt / FCF = -2.93 (Net Debt -687.0m / FCF TTM 234.5m)
Total Stockholder Equity = 824.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 20.69% (Net Income 217.6m / Total Assets 1.05b)
RoE = 26.39% (Net Income TTM 217.6m / Total Stockholder Equity 824.5m)
RoCE = 32.21% (EBIT 266.5m / Capital Employed (Equity 824.5m + L.T.Debt 2.89m))
RoIC = 24.02% (NOPAT 198.1m / Invested Capital 824.5m)
WACC = 9.07% (E(2.86b)/V(2.86b) * Re(9.08%) + (debt cost/tax rate unavailable))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.70%
[DCF Debug] Terminal Value 65.91% ; FCFE base≈229.4m ; Y1≈150.6m ; Y5≈68.9m
Fair Price DCF = 9.33 (DCF Value 1.15b / Shares Outstanding 122.9m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 62.80 | EPS CAGR: 71.48% | SUE: 2.76 | # QB: 1
Revenue Correlation: 95.71 | Revenue CAGR: 43.49% | SUE: 2.93 | # QB: 5

Additional Sources for CPRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle